ARTICLE | Product Development
Gritstone sending a mixed-modality COVID vaccine to Phase I
The regimen is optimized to induce strong T cell responses as well as strong antibody responses
January 20, 2021 3:00 AM UTC
NIAID and the Gates Foundation are betting Gritstone’s antigen delivery and T cell epitope prediction technologies can yield a COVID-19 vaccine with both potent CD8+ T cell immunity and neutralizing antibody responses.
The approach could also serve as a shield against the rise of SARS-CoV-2 variants resistant to the first tranche of vaccines...